In a prospective cohort, a 3-gene blood model predicted 1-year castration resistance with an AUC of 0.89 in metastatic hormone-sensitive prostate cancer.
|Articles|August 1, 1996
Oncology NEWS International
- Oncology NEWS International Vol 5 No 8
- Volume 5
- Issue 8
Number of US HIV Infections Steady
BETHESDA, Md--The number of Americans infected with HIV is holding steady at about 650,000 to 900,000, according to CDC data. This may be because the number of new HIV infections each year is roughly equal to the annual number of AIDS-related deaths, the report said.
Advertisement
BETHESDA, Md--The number of Americans infected with HIV is holdingsteady at about 650,000 to 900,000, according to CDC data. Thismay be because the number of new HIV infections each year is roughlyequal to the annual number of AIDS-related deaths, the reportsaid.
Articles in this issue
about 30 years ago
Chemo Improves Pain Relief in Advanced Prostate Cancerabout 30 years ago
NCCR Urges Congress to Support Senate Bill for Cancer Researchabout 30 years ago
Researchers Propose New Treatment Guidelines for HIVabout 30 years ago
Salvage Cryotherapy for Prostate Cancer Studied at M.D. Andersonabout 30 years ago
FNA Dropped From RDOG Study Due To High Rate of Insufficient Samplesabout 30 years ago
New Thinking on HIV Progression Leads to New Strategiesabout 30 years ago
Hospitals Told Not to Capitate for 'Wrong' Reasonsabout 30 years ago
More Study Needed of Possible Carcinogenesis of Winter Gas Additiveabout 30 years ago
President Makes NCAB AppointmentsAdvertisement
Related to this article
Rutika Mehta, MD, MPH, explains how she sequences MSI, HER2, claudin 18.2, and PD-L1 testing when tissue is limited in gastroesophageal cancer.
Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be candidates for triplet therapy.
Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.
Heath Skinner, MD, PhD, discussed the 3 considerations that determine which new radiation oncology service lines his network chooses to build.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.
Heath Skinner, MD, PhD, discussed which new radiation oncology service lines community practices can implement, how leadership decides, and what launches require.
Advertisement
Advertisement
Trending on CancerNetwork
1
Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy
2
CD19 CAR T Cell Therapy for Treatment-Refractory Seropositive Rheumatoid Arthritis: A Phase 1 Trial
3
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
4
Recapping GI Cancer at ESMO 2026: Standout Data From Phase 1 to Phase 3
5